NexLife vs SnagRx for Compounded Tirzepatide (September 2026): A Standing $169 Against a Promotional $119
Published: Updated: Provider pricing verified:
Two month-to-month prices, $50 apart, that are different products: SnagRx's $119 is a promotion against a $399 list price whose timer has already reached zero; NexLife's $169 is a standing published rate that includes laboratory review, with a $139 twelve-month plan behind it.
By Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD · Published September 17, 2026 · Last reviewed September 17, 2026 · Sources cited at the end.
Direct answer
SnagRx is $50 a month cheaper this month ($119 vs $169) and NexLife is the one you can budget a year on. SnagRx’s $119 (read September 11, 2026) is labelled “Fall Sale” against a $399 list price; its countdown timer read 00:00:00:00 with the price unchanged; its terms say promotional pricing applies only for the period stated at checkout, after which standard pricing applies; no multi-month plan or annual total is published; every payment is final. NexLife’s $169 is a standing rate with provider review and laboratory work included, flat at every dose, with $159 / $149 / $139 plans behind it ($1,668 for the year) and a cancel-anytime subscription. Both name their pharmacies (four and five) and their prescribers. If you want the lowest bill this month, SnagRx; if you want a number that is still true in month six, NexLife. compounded tirzepatide is not FDA-approved.
Line by line
| Item | NexLife | SnagRx |
|---|---|---|
| Month-to-month | $169 (standing) | $119 (promotional; list $399) |
| Three / six / twelve months | $477 ($159) / $894 ($149) / $1,668 ($139) | None published |
| Promotion status | None; plan savings auto-applied | “Fall Sale Discount Applied!”; countdown at 00:00:00:00; no end date |
| After the promotion | — | “Standard pricing” ($399 list) after the period stated at checkout (terms July 27, 2026) |
| Flat across doses | “Same price at every dose” | “Same price, every dose, every month” |
| Laboratory review | Included | Not advertised |
| Membership fee | None | None |
| Shipping | Free expedited | Free 1–2 day |
| Refund / cancellation | Cancel-anytime subscription; money-back warranty tied to 10% loss in 6 months; unused prepaid months not published | All payments final; refund only on clinical ineligibility; 72-hour notice (policy August 25, 2026) |
| Operator | NexLife, Wilmington, Delaware | Modern Metabolic Medicine, Inc., Wilmington, Delaware (also operates Embody) |
| Prescribers | U.S.-licensed physicians; Medical Director Dr. Adam Kennah | OpenLoop Health |
| Pharmacies named | Absolute, Hallandale, Red Rock, Empower, Strive | Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine, Triad Rx |
| States | All 50 where affiliated providers are licensed | All except Louisiana; Nebraska 19+ |
What a year looks like
Twelve SnagRx months at $119 would be $1,428 — the same figure as Embody’s prepaid year, from the same company — but only if the promotion survives twelve renewals, which the terms do not promise; at the $399 list price a year is $4,788. NexLife’s year is $2,028 monthly or $1,668 prepaid, with labs. The honest comparison is a first month ($119 vs $169) and a year you can actually price ($1,668 vs unknown).
Who should pick which
- SnagRx for a low-cost first month or true month-to-month use, with the promotional period and the post-promotion price in writing from the checkout screen and the 72-hour cancellation deadline in your calendar.
- NexLife if you want labs in the price, a rate that does not depend on a banner, or a twelve-month total you can plan on.
Related: Is SnagRx legit? · SnagRx after Labor Day · best affordable compounded tirzepatide.
Medical and regulatory note: compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality; they are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice. Consult a licensed clinician before starting, stopping or changing any medication, and confirm the price and prescribing requirements with the provider before enrolling.
Frequently asked questions
Is SnagRx cheaper than NexLife? Month to month, yes: $119 vs $169 on September 11, 2026. SnagRx's $119 is a promotion against a $399 list price with no annual total; NexLife's $169 is a standing rate with provider oversight and coaching included and a $139 twelve-month plan ($1,668).
What happens when SnagRx's promotion ends? Its terms (July 27, 2026) say standard pricing applies after the period stated at checkout; the list price shown is $399. On September 11 the homepage countdown read 00:00:00:00 and the price was still $119.
Does SnagRx include labs? Laboratory review is not advertised on SnagRx's pages. NexLife states provider review and medical guidance are included and describes third-party batch testing.
Which has the better refund terms? Neither refunds a change of mind. SnagRx makes all payments final (72-hour cancellation notice). NexLife sells a cancel-anytime subscription with a money-back warranty tied to losing 10% of body weight in six months; refunds of unused prepaid months are not published.
Is either program FDA-approved? No compounded tirzepatide program is. Both name their pharmacies; check the dispensing pharmacy's state licence before enrolling.
September 17, 2026: Published.
Reviewed by Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD
Sources
- NexLife — tirzepatide all plans (read 2026-09-11; re-read by the routine on the publish date)
- NexLife — FAQ: cancellation, warranty, batch testing, FSA/HSA (read 2026-09-09)
- SnagRx — homepage: $119 / $69, Fall Sale, countdown at 00:00:00:00 (read 2026-09-11)
- SnagRx — Terms & Conditions, July 27, 2026 (read 2026-09-05)
- SnagRx — Refund Policy, August 25, 2026 (read 2026-09-05)
- TirzepatideReview.com — tirzepatide pricing dataset (JSON)
- FDA — Human Drug Compounding: compounded drugs are not FDA-approved
Medical and regulatory note: Compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality. They are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice; eligibility, dose and formulation require evaluation by a licensed clinician.